These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Anti-Xa activity with low-molecular-weight heparin, enoxaparin, during pregnancy in women with mechanical heart valves. Izaguirre R; De La Peña A; Ramírez A; Cortina E; Huerta M; Salazar E Proc West Pharmacol Soc; 2002; 45():127-8. PubMed ID: 12434554 [No Abstract] [Full Text] [Related]
27. [Anticoagulant therapy during pregnancy in patients with mechanical valvular prostheses]. Hanania G; Nassivera L Arch Mal Coeur Vaiss; 2001 Oct; 94(10):1073-6. PubMed ID: 11725712 [TBL] [Abstract][Full Text] [Related]
29. A benchmark for platelet count monitoring with low-molecular-weight heparin: expanding implementation of National Patient Safety Goals. Spinler SA Ann Pharmacother; 2009 Sep; 43(9):1519-21. PubMed ID: 19690223 [TBL] [Abstract][Full Text] [Related]
30. Heparin and low molecular weight heparin in thrombosis and beyond. Mousa SA Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411 [TBL] [Abstract][Full Text] [Related]
31. [Anticoagulation using low-molecular-weight heparin--interview with Regina Burian]. Hartmann A Hamostaseologie; 2005 Nov; 25(4):405-6. PubMed ID: 16402488 [No Abstract] [Full Text] [Related]
32. Treatment with low molecular weight heparin needs anticoagulation monitoring. Hassn A; Hassan AM J Am Coll Surg; 1999 Jul; 189(1):141-2. PubMed ID: 10401753 [No Abstract] [Full Text] [Related]
33. Perioperative bridging therapy for the at-risk patient on chronic anticoagulation. Spyropoulos AC Dis Mon; 2005; 51(2-3):183-93. PubMed ID: 15900271 [No Abstract] [Full Text] [Related]
34. Low-molecular-weight heparin in pregnant women with prosthetic heart valves. Descarries LM; Leduc L; Khairy P; Mercier LA J Heart Valve Dis; 2006 Sep; 15(5):679-85. PubMed ID: 17044374 [TBL] [Abstract][Full Text] [Related]
35. Heparins, low-molecular-weight heparins, and pentasaccharides. Dinwoodey DL; Ansell JE Clin Geriatr Med; 2006 Feb; 22(1):1-15, vii. PubMed ID: 16377464 [TBL] [Abstract][Full Text] [Related]
36. [Use of LMW heparin: information for prescribers. Update: 10 April 2002]. Agence Française de Sécurité Sanitaire Des Produits de Santé (AFSSAPS) J Mal Vasc; 2002 Oct; 27(4):231-3. PubMed ID: 12457130 [No Abstract] [Full Text] [Related]
37. A contemporary assessment of low-molecular-weight heparin for the treatment of acute coronary syndromes: factoring in new trials and meta-analysis data. Topol EJ Am Heart J; 2005 Apr; 149(4 Suppl):S100-6. PubMed ID: 16124950 [No Abstract] [Full Text] [Related]
38. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience]. Míka P; Behounek J; Skoták M; Nevsímal L Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102 [TBL] [Abstract][Full Text] [Related]
39. Deep vein thrombosis and cancer: survival, recurrence, and anticoagulant choices. Lee AY Dis Mon; 2005; 51(2-3):150-7. PubMed ID: 15900267 [No Abstract] [Full Text] [Related]
40. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Greaves M; Thromb Haemost; 2002 Jan; 87(1):163-4. PubMed ID: 11848446 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]